Literature DB >> 1652947

HIV-1 proteinase is required for synthesis of pro-viral DNA.

C Baboonian1, A Dalgleish, L Bountiff, J Gross, S Oroszlan, G Rickett, C Smith-Burchnell, P Troke, J Merson.   

Abstract

HIV-1 proteinase activity is thought to occur primarily post-integration by cleaving the viral Gag and Gag-Pol polyproteins. Its role in the pre-integration stages of viral replication, however, has not been studied in detail. Here we report that a synthetic peptide analogue, UK-88,947, which is a specific inhibitor of purified HIV-1 proteinase, inhibits the processing of the viral polyproteins in cultures of HIV-1 infected cells and prevents the formation of mature, infectious virions. Analysis of DNA from HIV-1 infected cells treated with UK-88,947 showed that viral DNA synthesis was inhibited when the compound was added to cultures one hour before infection. Similar results were obtained when AZT was used. Neither HIV-1 reverse transcriptase or the replication of FIV are inhibited by UK-88,947.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652947     DOI: 10.1016/0006-291x(91)91327-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.

Authors:  H Jacobsen; L Ahlborn-Laake; R Gugel; J Mous
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

Authors:  A H Kaplan; M Manchester; T Smith; Y L Yang; R Swanstrom
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Molecular analysis of the feline immunodeficiency virus protease: generation of a novel form of the protease by autoproteolysis and construction of cleavage-resistant proteases.

Authors:  G S Laco; M C Fitzgerald; G M Morris; A J Olson; S B Kent; J H Elder
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.

Authors:  H Zhang; G Dornadula; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 6.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

7.  Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus.

Authors:  J H Elder; M Schnölzer; C S Hasselkus-Light; M Henson; D A Lerner; T R Phillips; P C Wagaman; S B Kent
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.

Authors:  K Nagy; M Young; C Baboonian; J Merson; P Whittle; S Oroszlan
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells.

Authors:  D M Lambert; S R Petteway; C E McDanal; T K Hart; J J Leary; G B Dreyer; T D Meek; P J Bugelski; D P Bolognesi; B W Metcalf
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  A p6Pol-protease fusion protein is present in mature particles of human immunodeficiency virus type 1.

Authors:  N Almog; R Roller; G Arad; L Passi-Even; M A Wainberg; M Kotler
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.